Corporate News

Scientific presentations on hyperpolarized ¹²⁹Xenon at upcoming medical meetings

• Polarean’s investigational drug/device lung diagnostic to be prominently featured
• Multiple hyperpolarized Xenon MRI presentations to be highlighted at two major upcoming scientific conferences

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination diagnostic for the magnetic resonance imaging (MRI) market, announces a number of presentations highlighting the use of hyperpolarized Xenon 129 (“¹²⁹Xe”) will be made by leading academic researchers at the upcoming American Thoracic Society (“ATS”) virtual conference and the International Society for Magnetic Resonance in Medicine (“ISMRM”) virtual conference. The ATS and ISMRM conferences are taking place between 5-10 August 2020 and 8-14 August 2020, respectively.

Over 40 abstracts related to the use of hyperpolarized ¹²⁹Xe were accepted for presentation at ATS 2020. The abstracts listed below are among those that will be presented as posters on Wednesday, 5 August 2020:

Presentations of the following accepted abstracts will be delivered at ISMRM on the following days and times:

Additionally, Talissa Altes, MD, Professor and Chair of Radiology at the University of Missouri will be delivering a presentation on Xenon lung magnetic resonance imaging (MRI) during the Lung/Thoracic MRI Session W-02 during ISMRM.  Session W-02 takes place on Tuesday, 11 August from 1:45 to 2:30 p.m. ET.

Richard Hullihen, Chief Executive Officer of Polarean commented: “We are pleased to see ¹²⁹Xenon in MRI highlighted at these key scientific meetings. It is a testament to the growing interest in exploring hyperpolarized ¹²⁹Xenon as a way of advancing the use of MRI in a non-invasive, non-ionizing functional imaging platform to assist with the early diagnosis of respiratory diseases. As well as this, it can be used to monitor progression and therapeutic response in the patient. Many of the projects being presented at these two leading conferences have made use of Polarean’s products to conduct research, highlighting the growing academic acceptance of the Company’s technology. We hope that the inclusion of so many sessions on ¹²⁹Xenon will continue to showcase Polarean’s important work in the field as we continue to progress discussions with the regulator regarding the clinical use of our drug-device system.”

Contacts:

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical drug-device combination companies operating in the high-resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarized Xenon gas (¹²⁹Xe) as an imaging agent to visualize ventilation.¹²⁹Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung, and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group also develops high performance MRI radiofrequency (RF) coils which are a required component for imaging ¹²⁹Xe in the MRI system. The development of these coils by the Group facilitates emerging applications.

Scientific presentations on hyperpolarized ¹²⁹Xenon at upcoming medical meetings

• Polarean’s investigational drug/device lung diagnostic to be prominently featured
• Multiple hyperpolarized Xenon MRI presentations to be highlighted at two major upcoming scientific conferences

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination diagnostic for the magnetic resonance imaging (MRI) market, announces a number of presentations highlighting the use of hyperpolarized Xenon 129 (“¹²⁹Xe”) will be made by leading academic researchers at the upcoming American Thoracic Society (“ATS”) virtual conference and the International Society for Magnetic Resonance in Medicine (“ISMRM”) virtual conference. The ATS and ISMRM conferences are taking place between 5-10 August 2020 and 8-14 August 2020, respectively.

Over 40 abstracts related to the use of hyperpolarized ¹²⁹Xe were accepted for presentation at ATS 2020. The abstracts listed below are among those that will be presented as posters on Wednesday, 5 August 2020:

Presentations of the following accepted abstracts will be delivered at ISMRM on the following days and times:

Additionally, Talissa Altes, MD, Professor and Chair of Radiology at the University of Missouri will be delivering a presentation on Xenon lung magnetic resonance imaging (MRI) during the Lung/Thoracic MRI Session W-02 during ISMRM.  Session W-02 takes place on Tuesday, 11 August from 1:45 to 2:30 p.m. ET.

Richard Hullihen, Chief Executive Officer of Polarean commented: “We are pleased to see ¹²⁹Xenon in MRI highlighted at these key scientific meetings. It is a testament to the growing interest in exploring hyperpolarized ¹²⁹Xenon as a way of advancing the use of MRI in a non-invasive, non-ionizing functional imaging platform to assist with the early diagnosis of respiratory diseases. As well as this, it can be used to monitor progression and therapeutic response in the patient. Many of the projects being presented at these two leading conferences have made use of Polarean’s products to conduct research, highlighting the growing academic acceptance of the Company’s technology. We hope that the inclusion of so many sessions on ¹²⁹Xenon will continue to showcase Polarean’s important work in the field as we continue to progress discussions with the regulator regarding the clinical use of our drug-device system.”

Contacts:

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical drug-device combination companies operating in the high-resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarized Xenon gas (¹²⁹Xe) as an imaging agent to visualize ventilation.¹²⁹Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung, and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group also develops high performance MRI radiofrequency (RF) coils which are a required component for imaging ¹²⁹Xe in the MRI system. The development of these coils by the Group facilitates emerging applications.

Scientific presentations on hyperpolarized ¹²⁹Xenon at upcoming medical meetings

• Polarean’s investigational drug/device lung diagnostic to be prominently featured
• Multiple hyperpolarized Xenon MRI presentations to be highlighted at two major upcoming scientific conferences

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination diagnostic for the magnetic resonance imaging (MRI) market, announces a number of presentations highlighting the use of hyperpolarized Xenon 129 (“¹²⁹Xe”) will be made by leading academic researchers at the upcoming American Thoracic Society (“ATS”) virtual conference and the International Society for Magnetic Resonance in Medicine (“ISMRM”) virtual conference. The ATS and ISMRM conferences are taking place between 5-10 August 2020 and 8-14 August 2020, respectively.

Over 40 abstracts related to the use of hyperpolarized ¹²⁹Xe were accepted for presentation at ATS 2020. The abstracts listed below are among those that will be presented as posters on Wednesday, 5 August 2020:

Presentations of the following accepted abstracts will be delivered at ISMRM on the following days and times:

Additionally, Talissa Altes, MD, Professor and Chair of Radiology at the University of Missouri will be delivering a presentation on Xenon lung magnetic resonance imaging (MRI) during the Lung/Thoracic MRI Session W-02 during ISMRM.  Session W-02 takes place on Tuesday, 11 August from 1:45 to 2:30 p.m. ET.

Richard Hullihen, Chief Executive Officer of Polarean commented: “We are pleased to see ¹²⁹Xenon in MRI highlighted at these key scientific meetings. It is a testament to the growing interest in exploring hyperpolarized ¹²⁹Xenon as a way of advancing the use of MRI in a non-invasive, non-ionizing functional imaging platform to assist with the early diagnosis of respiratory diseases. As well as this, it can be used to monitor progression and therapeutic response in the patient. Many of the projects being presented at these two leading conferences have made use of Polarean’s products to conduct research, highlighting the growing academic acceptance of the Company’s technology. We hope that the inclusion of so many sessions on ¹²⁹Xenon will continue to showcase Polarean’s important work in the field as we continue to progress discussions with the regulator regarding the clinical use of our drug-device system.”

Contacts:

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical drug-device combination companies operating in the high-resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarized Xenon gas (¹²⁹Xe) as an imaging agent to visualize ventilation.¹²⁹Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung, and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group also develops high performance MRI radiofrequency (RF) coils which are a required component for imaging ¹²⁹Xe in the MRI system. The development of these coils by the Group facilitates emerging applications.

2020

Scientific presentations on hyperpolarized ¹²⁹Xenon at upcoming medical meetings

• Polarean’s investigational drug/device lung diagnostic to be prominently featured
• Multiple hyperpolarized Xenon MRI presentations to be highlighted at two major upcoming scientific conferences

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination diagnostic for the magnetic resonance imaging (MRI) market, announces a number of presentations highlighting the use of hyperpolarized Xenon 129 (“¹²⁹Xe”) will be made by leading academic researchers at the upcoming American Thoracic Society (“ATS”) virtual conference and the International Society for Magnetic Resonance in Medicine (“ISMRM”) virtual conference. The ATS and ISMRM conferences are taking place between 5-10 August 2020 and 8-14 August 2020, respectively.

Over 40 abstracts related to the use of hyperpolarized ¹²⁹Xe were accepted for presentation at ATS 2020. The abstracts listed below are among those that will be presented as posters on Wednesday, 5 August 2020:

Presentations of the following accepted abstracts will be delivered at ISMRM on the following days and times:

Additionally, Talissa Altes, MD, Professor and Chair of Radiology at the University of Missouri will be delivering a presentation on Xenon lung magnetic resonance imaging (MRI) during the Lung/Thoracic MRI Session W-02 during ISMRM.  Session W-02 takes place on Tuesday, 11 August from 1:45 to 2:30 p.m. ET.

Richard Hullihen, Chief Executive Officer of Polarean commented: “We are pleased to see ¹²⁹Xenon in MRI highlighted at these key scientific meetings. It is a testament to the growing interest in exploring hyperpolarized ¹²⁹Xenon as a way of advancing the use of MRI in a non-invasive, non-ionizing functional imaging platform to assist with the early diagnosis of respiratory diseases. As well as this, it can be used to monitor progression and therapeutic response in the patient. Many of the projects being presented at these two leading conferences have made use of Polarean’s products to conduct research, highlighting the growing academic acceptance of the Company’s technology. We hope that the inclusion of so many sessions on ¹²⁹Xenon will continue to showcase Polarean’s important work in the field as we continue to progress discussions with the regulator regarding the clinical use of our drug-device system.”

Contacts:

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical drug-device combination companies operating in the high-resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarized Xenon gas (¹²⁹Xe) as an imaging agent to visualize ventilation.¹²⁹Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung, and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group also develops high performance MRI radiofrequency (RF) coils which are a required component for imaging ¹²⁹Xe in the MRI system. The development of these coils by the Group facilitates emerging applications.

Scientific presentations on hyperpolarized ¹²⁹Xenon at upcoming medical meetings

• Polarean’s investigational drug/device lung diagnostic to be prominently featured
• Multiple hyperpolarized Xenon MRI presentations to be highlighted at two major upcoming scientific conferences

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination diagnostic for the magnetic resonance imaging (MRI) market, announces a number of presentations highlighting the use of hyperpolarized Xenon 129 (“¹²⁹Xe”) will be made by leading academic researchers at the upcoming American Thoracic Society (“ATS”) virtual conference and the International Society for Magnetic Resonance in Medicine (“ISMRM”) virtual conference. The ATS and ISMRM conferences are taking place between 5-10 August 2020 and 8-14 August 2020, respectively.

Over 40 abstracts related to the use of hyperpolarized ¹²⁹Xe were accepted for presentation at ATS 2020. The abstracts listed below are among those that will be presented as posters on Wednesday, 5 August 2020:

Presentations of the following accepted abstracts will be delivered at ISMRM on the following days and times:

Additionally, Talissa Altes, MD, Professor and Chair of Radiology at the University of Missouri will be delivering a presentation on Xenon lung magnetic resonance imaging (MRI) during the Lung/Thoracic MRI Session W-02 during ISMRM.  Session W-02 takes place on Tuesday, 11 August from 1:45 to 2:30 p.m. ET.

Richard Hullihen, Chief Executive Officer of Polarean commented: “We are pleased to see ¹²⁹Xenon in MRI highlighted at these key scientific meetings. It is a testament to the growing interest in exploring hyperpolarized ¹²⁹Xenon as a way of advancing the use of MRI in a non-invasive, non-ionizing functional imaging platform to assist with the early diagnosis of respiratory diseases. As well as this, it can be used to monitor progression and therapeutic response in the patient. Many of the projects being presented at these two leading conferences have made use of Polarean’s products to conduct research, highlighting the growing academic acceptance of the Company’s technology. We hope that the inclusion of so many sessions on ¹²⁹Xenon will continue to showcase Polarean’s important work in the field as we continue to progress discussions with the regulator regarding the clinical use of our drug-device system.”

Contacts:

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical drug-device combination companies operating in the high-resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarized Xenon gas (¹²⁹Xe) as an imaging agent to visualize ventilation.¹²⁹Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung, and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group also develops high performance MRI radiofrequency (RF) coils which are a required component for imaging ¹²⁹Xe in the MRI system. The development of these coils by the Group facilitates emerging applications.

Scientific presentations on hyperpolarized ¹²⁹Xenon at upcoming medical meetings

• Polarean’s investigational drug/device lung diagnostic to be prominently featured
• Multiple hyperpolarized Xenon MRI presentations to be highlighted at two major upcoming scientific conferences

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination diagnostic for the magnetic resonance imaging (MRI) market, announces a number of presentations highlighting the use of hyperpolarized Xenon 129 (“¹²⁹Xe”) will be made by leading academic researchers at the upcoming American Thoracic Society (“ATS”) virtual conference and the International Society for Magnetic Resonance in Medicine (“ISMRM”) virtual conference. The ATS and ISMRM conferences are taking place between 5-10 August 2020 and 8-14 August 2020, respectively.

Over 40 abstracts related to the use of hyperpolarized ¹²⁹Xe were accepted for presentation at ATS 2020. The abstracts listed below are among those that will be presented as posters on Wednesday, 5 August 2020:

Presentations of the following accepted abstracts will be delivered at ISMRM on the following days and times:

Additionally, Talissa Altes, MD, Professor and Chair of Radiology at the University of Missouri will be delivering a presentation on Xenon lung magnetic resonance imaging (MRI) during the Lung/Thoracic MRI Session W-02 during ISMRM.  Session W-02 takes place on Tuesday, 11 August from 1:45 to 2:30 p.m. ET.

Richard Hullihen, Chief Executive Officer of Polarean commented: “We are pleased to see ¹²⁹Xenon in MRI highlighted at these key scientific meetings. It is a testament to the growing interest in exploring hyperpolarized ¹²⁹Xenon as a way of advancing the use of MRI in a non-invasive, non-ionizing functional imaging platform to assist with the early diagnosis of respiratory diseases. As well as this, it can be used to monitor progression and therapeutic response in the patient. Many of the projects being presented at these two leading conferences have made use of Polarean’s products to conduct research, highlighting the growing academic acceptance of the Company’s technology. We hope that the inclusion of so many sessions on ¹²⁹Xenon will continue to showcase Polarean’s important work in the field as we continue to progress discussions with the regulator regarding the clinical use of our drug-device system.”

Contacts:

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical drug-device combination companies operating in the high-resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarized Xenon gas (¹²⁹Xe) as an imaging agent to visualize ventilation.¹²⁹Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung, and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group also develops high performance MRI radiofrequency (RF) coils which are a required component for imaging ¹²⁹Xe in the MRI system. The development of these coils by the Group facilitates emerging applications.